Literature DB >> 9376125

KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts.

Y Hirasawa1, N Kohno, A Yokoyama, Y Inoue, M Abe, K Hiwada.   

Abstract

KL-6 in serum and bronchoalveolar lavage fluid has been reported to be a sensitive marker indicating the activity of fibrosing lung diseases. The molecule is clustered in MUC1 mucin according to the findings of immunohistochemical and cytometric studies. To elucidate the pathogenic role of KL-6 in fibrosing lung disease, we characterized its biochemical properties and examined whether purified KL-6 is chemotactic for human fibroblasts in vitro using modified Boyden chambers. Biochemical properties of purified KL-6 were similar to those of other MUC1 mucins previously reported. KL-6 promoted the migration of 5 of 5 human lung fibroblasts and 3 of 4 human skin fibroblasts. Checkerboard analysis revealed that KL-6 was chemotactic as well as chemokinetic. Though platelet-derived growth factor, fibroblast growth factor, or fibronectin were also chemotactic for fibroblasts in the experimental system, only fibronectin augmented KL-6-induced chemotaxis. These observations indicate that KL-6 is one of the chemotactic factors for most fibroblasts and that the increased KL-6 in the epithelial lining fluid in small airways may cause the intra-alveolar fibrosis in fibrosing lung diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9376125     DOI: 10.1165/ajrcmb.17.4.2253

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  49 in total

1.  Prevention of lung injury by Muc1 mucin in a mouse model of repetitive Pseudomonas aeruginosa infection.

Authors:  Tsuyoshi Umehara; Kosuke Kato; Yong Sung Park; Erik P Lillehoj; Hideyuki Kawauchi; Kwang Chul Kim
Journal:  Inflamm Res       Date:  2012-05-29       Impact factor: 4.575

2.  Examination of changes in TGF-beta1 and KL-6 expression over time in patients with chronic hepatitis C by AT-II receptor blocker therapy.

Authors:  Takeshi Kurihara; Atsushi Maeda; Mutsuo Shigemoto; Katsuko Yamashita
Journal:  J Gastroenterol       Date:  2005-08       Impact factor: 7.527

3.  Comparison of pulmonary thin section CT findings and serum KL-6 levels in patients with sarcoidosis.

Authors:  K Honda; F Okada; Y Ando; H Mori; K Umeki; H Ishii; J Kadota; M Ando; E Miyazaki; T Kumamoto
Journal:  Br J Radiol       Date:  2010-11-02       Impact factor: 3.039

Review 4.  Peripheral blood biomarkers in idiopathic pulmonary fibrosis.

Authors:  Rekha Vij; Imre Noth
Journal:  Transl Res       Date:  2012-02-02       Impact factor: 7.012

5.  TNF-α is a key regulator of MUC1, an anti-inflammatory molecule, during airway Pseudomonas aeruginosa infection.

Authors:  Seongwon Choi; Yong Sung Park; Takeshi Koga; Allison Treloar; Kwang Chul Kim
Journal:  Am J Respir Cell Mol Biol       Date:  2010-05-06       Impact factor: 6.914

Review 6.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

Review 7.  Molecular biomarkers in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Kevin K Brown; Harold R Collard
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-09-26       Impact factor: 5.464

8.  Usefulness of quantifying serum KL-6 levels in the follow-up of uveitic patients with sarcoidosis.

Authors:  Nobuyoshi Kitaichi; Toshihide Ariga; Satoru Kase; Kauzhiko Yoshida; Kenichi Namba; Shigeaki Ohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-23       Impact factor: 3.117

9.  Increase of KL-6 in sera of uveitis patients with sarcoidosis.

Authors:  Nobuyoshi Kitaichi; Satoshi Kotake; Hitoshi Shibuya; Yukiho Yamada; Hitoshi Chiba; Kenichi Namba; Shigeaki Ohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-11       Impact factor: 3.117

10.  Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study.

Authors:  Yasuo Shimizu; Noriaki Sunaga; Kunio Dobashi; Makoto Fueki; Naoto Fueki; Sohei Makino; Masatomo Mori
Journal:  BMC Infect Dis       Date:  2009-04-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.